Despite advancements in cardiac transplant therapies, rejection remains a significant issue. Lovastatin, a statin drug with promising immunomodulatory effects, has garnered attention as a potential treatment for heart transplant rejection. Studies collectively highlight the ability of lovastatin to influence T-cell activation, reduce episodes of acute rejection, and maintain graft function. These findings offer promising avenues for enhancing transplant success rates and patient outcomes with the use of lovastatin. This survey aimed to explore perceptions of the use of lovastatin in the management of post-cardiac transplant rejection. Participants with diverse backgrounds were surveyed about their candidacy for lovastatin, perceived risks of non-approved drugs, and dyslipidemia prophylaxis importance. Analysis of 39 respondents revealed demographic trends, predominantly female (59%) and aged 18-24 years (82.1%), primarily from Maryland and Virginia. Most were already employed, many in pharmacy-related roles, and had a 4-year degree as their highest level of education. While 70.3% recognized lovastatin as a statin, opinions on its efficacy varied. Notably, 51.4% believed it should be considered for the management of rejection. Demographic comparisons revealed significant differences in opinions, such as age groups differing in lovastatin's suitability (P = 0.003) and awareness of unapproved medications (P < 0.001). This study highlights the diverse views on the effectiveness of lovastatin for heart transplant rejection and emphasizes the need for further investigation. Patient education and prevention of dyslipidemia are essential for transplant survival. Given the array of viewpoints, further research is warranted to clarify the safety and effectiveness of lovastatin in this context.
IJPRAS
